Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth Academic Article Article uri icon


MeSH Major

  • Glioblastoma
  • Surveys and Questionnaires


  • Chronic systemic delivery of therapeutic proteins, such as inhibitors of angiogenesis, present a number of difficult pharmacological challenges. To overcome these problems for one such protein, we constructed retroviral and adenoviral vectors that express a novel, secretable form of the antiangiogenic protein, platelet factor 4 (sPF4). Vector-mediated sPF4 transduction selectively inhibits endothelial cell proliferation in vitro, and results in hypovascular tumors that grow slowly in vivo. Additionally, tumor-associated angiogenesis is inhibited and animal survival is prolonged, following transduction of established intracerebral gliomas by an sPF4-expressing adenoviral vector. These data support the concept that targeted antiangiogenesis, using virally mediated gene transfer, represents a promising strategy for delivering antiangiogenic therapy.

publication date

  • April 15, 1997



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1038/nm0497-437

PubMed ID

  • 9095178

Additional Document Info

start page

  • 437

end page

  • 42


  • 3


  • 4